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Background : Ethambutol(EMB) is one of the first-line drugs included in short-course anti-tuberculosis therapy. The 
point mutations in embB gene have been speculated to be associated EMB resistance. However, detection of embB 
mutations at these positions have been observed in both EMB-susceptible isolates; thus, it remains controversial whether 
these mutations are associated with EMB resistance
Methods : The 36 M. tuberculosis isolates were selected from clinical isolates which tested susceptible to EMB and 
resistant to at least one drug. DNA extracted from the isolates was analyzed by amplifying embB gene. The PCR products 
were purified and directly sequenced. We reviewed the history of past drug susceptibility test results.
Results : Out of 36 EMB-susceptible strains, 3 strains (8.3%) had a mutation in codon 306 or 406 of the embB gene. 
These three strains had at least isoniazid resistance. They grew at 1.0 mcg/ml of EMB in Lowenstein-Jensen media. 
The patients of the strains were continuously smear-positive for over 3 years despite taking TB therapy. One strain 
had been EMB-resistant in past drug susceptibility tests. 
Conclusion : EMB-susceptible strains containing embB mutation may be caused by decreased viability in vitro test 
not by itself.  (Tuberc Respir Dis 2005; 59: 266-271)
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INTRODUCTION
Ethambutol (EMB), [dextro-2,2’-(ethylenediimi󰠀
no)di-1-butanol], a synthetic compound with str󰠀
uctural similarity to D-arabinose, was first intro󰠀
duced in 19611. It is one of the first-line drugs in󰠀
cluded in short-course anti-tuberculosis therapy in 
combination with isoniazid (INH), rifampicin (RMP), 
and pyrazinamide (PZA). Even though the spectrum 
of activity of EMB includes Mycobacterium tube󰠀
rculosis and non-tuberculous mycobacteria, the 
precise mode of EMB and the molecular basis of 
resistance are not fully understood. Since the 
discovery of three contiguous embCAB genes en󰠀
coding membrane-associated arabinosyl transferase 
involved in the polymerization of the cell wall 
arabinan2,3, the point mutations at position 306, 
406, 497 in these genes have been speculated to be 
associated EMB resistance3,4,5,6. However, detection 
of embB mutations at these positions have been 
observed in both EMB-susceptible and EMB-resi󰠀
stant isolates; thus, it remains controversial whe󰠀
ther these mutations are associated with EMB re󰠀
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Primer Sequences Nucleotides PCR product size (bp)
embB1F
embB1R
embB2F
embB2R
embB3F
embB3R
katGF
katGR
ahpCF
ahpCR
rpoBF
rpoBR
gyrAF
gyrAR
5’ AGCTCCTCCTCAGGCCGTTC 3’
5’ CAGACTGGCGTCGCTGACAT 3’
5’ AGTGTGCTGGCTGCTGCTGT 3’
5’ CAGTGTGAATGCGGCGGTAA 3’
5’ TTACCGCCGCATTCACACTG 3’
5’ ACCCTGGTGGCTTCCAACAC 3’
5’ TGGGGCTGATCTACGTGAACC 3’
5’ CCCACTCGTAGCCGTACAGG 3’
5’ GAGACCGGCTTCCGACCACC 3’
5’ GCTGGTAGGCGGGGAATTGAT 3’
5’ TGGTCCGCTTGCACGAGGGTCAGA 3’
5’ CCCTCAGGGGTTTCGATCGG 3’
5’ GCCGAGACCATGGGCAACTA 3’
5’ TCAGCATCTCCATCGCCAAC 3’
4247259-79
4247535-54
4247587-606
4247817-36
4247817-36
4248014-33
2155416-36
2155086-105
2725941-57
2726213-33
760820-43
761239-58
7533-52
7708-28
296
250
217
351
293
439
196
* Nucleotides number of primers was from NC000962
Table 1. Oligonucleotide primer sequences for amplification of the embB, katG, ahpC, rpoB, gyrA genes
sistance7,8. The aim of this work is to better un󰠀
derstand the presence of embB mutations among 
clinical EMB-susceptible isolates, drawing from 
various viewpoints, such as drug susceptibility tests 
with subdivided EMB concentration, screening of 
genotyping, and patient history. 
MATERIALS AND METHODS
Drug susceptibility testing
The 36 M. tuberculosis isolates for this study 
were randomly selected from clinical isolates which 
tested susceptible to EMB and resistant to at least 
one drug according to drug susceptibility testing 
(DST) performed in May 2004 at the Korean 
Institute of Tuberculosis. DST for anti-TB drugs 
was performed on Lowenstein-Jensen (LJ) media 
by the method of absolute concentration9. The drug 
concentrations for susceptibility testing were as 
follows; isoniazid (INH), 0.2mcg/ml; streptomycin 
(SM), 4mcg/ml; rifampicin (RMP) 40mcg/ml; eth󰠀
ambutol (EMB), 2mcg/ml; kanamycin (KM), 40mcg/ 
ml; capreomycin (CM), 40mcg/ml; ethionamide (ETH), 
40 mcg/ml; cycloserine (CS), 30mcg/ml; p-aminosalicylic 
acid (PAS), 1mcg/ml; ofloxaxin (OFX), 2mcg/ml. DST 
for pyrazinamide (PZA) was done by pyrazinamidase 
test9.
   
Genotyping and review of patient history
IS6110 profiling was done according to standard 
procedures to determine if the isolates were epide󰠀
miologically independent10. DNA extracted from 
the isolates was analyzed by amplifying four frag󰠀
ments, using the PCR primers shown in Table 1. 
The PCR (annealing temperature: 65℃) products 
were purified (QIAquick PCR purification kit or 
QIAquick gel extraction kit; QIAGEN) and directly 
sequenced using the BigDye Terminator sequencing 
kit and the ABI PRISM 377 automated sequencer  
(PE Biosystems, Branchiburg, NJ). We contacted 
the clinical doctor who treated the patients for the 
treatment history, and reviewed the history of past 
DST results in Korean Institute of Tuberculosis.  
RESULTS 
Among the thirty-six randomly-selected strains, 
three (8.3%) revealed an embB mutation after se󰠀
quencing analysis. One of three strains had a mu󰠀
tation at codon 306 (OPR1776) in the embB gene, 
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Strain OPR1776 LR447 OPR2300
embB mutation Met306Ile Gly406Asp Gly406Asp
Drug resistance H (Mar. 2000)
H, R (Jun. 2000)
H, R, K (Nov. 2000)
H, R, K, Z (Oct. 2001)
H, R, K, O, Z (May. 2004)
H, R, E, K, O, Z (Jul. 2004)
H, R, K, O, Z (Sep. 2004)
H, R, E, K, O, Z (Nov. 2004)
H, R (Oct. 2001)
H, R, E, O (Jun. 2002)
H, O (May. 2004)
H 
(May.2004)
Gene mutation related 
INH resistance ahpC, 6UPS; G->A
katG
Ser 315 Thr
katG
Ser 315 Thr
rpoB mutation His 526 Tyr Asp 516Tyr Asp516Tyr
gyrA mutation Asp94His - -
* H, R, E, K, O, Z: isoniazid, rifampicin, ethambutol, kanamycin, ofloxacin, pyrazinamide respectively. UPS; nucleotide 
position (base pairs) upstream of the transcriptional start site.
Table 2. Characteristics of three strains with embB mutations among 36 EMB-susceptible strains 
while the mutations in other two strains were 
located in codon 406 (LR447, OPR2300). 
Phenotypical profile of OPR1776 showed resistance 
to INH, RMP, OFX, KM, PZA; additional mutations 
in ahpC, rpoB, gyrA genes that correlate with drug 
resistance were also present. Reviewing the past 
DST results of OPR1776, the strain started with 
INH mono-resistance in March 2000. The patient 
continuously discharged bacilli despite treatment 
compliance, and the strain steadily acquired addi󰠀
tional drug resistance to RMP, KM, OFX, and PZA 
according to DST performed in May 2004. There󰠀
after, DST results to EMB varied: the strain was 
EMB-resistant in June 2004, EMB-susceptible in 
September 2004, and then EMB-resistant in No󰠀
vember 2004 (Table 2). 
DST results of LR447 showed resistance to INH, 
OFX with mutations in katG and rpoB genes. This 
strain was phenotypically susceptible at 40 mcg/ml 
of RMP despite the presence of an rpoB mutation. 
The patient with LR447 was continuously smear- 
positive from 2001 to 2004. According to past DST 
results, this isolate was resistant to INH and RMP 
in October 2001. The strain then developed addi󰠀
tional resistance to EMB and OFX in July 2002. 
Thereafter, the patient refused to further TB the󰠀
rapy until 2004. DST performed in May 2004 demon󰠀
strated resistance to only INH and OFX (Table 2).
The OPR2300 strain had only INH resistance on 
LJ media even though it had possessed mutations 
in katG and rpoB genes. Unfortunately, we could 
not get further clinical data, because the patient of 
OPR2300 did not come to the hospital to receive 
treatment and her treating physician could not 
provide any further treatment history. Serial DSTs 
to this patient were not performed at the Korean 
Institute of Tuberculosis (Table 2). 
We investigated the inhibitory concentrations of 
three pan-susceptible and four EMB-resistant str󰠀
ains, and of these three strains containing embB 
mutations but with phenotypic EMB susceptibility. 
The three pan-susceptible strains were completely 
inhibited at 1 mcg/ml of EMB, while 2 of the 3 
strains with embB mutations and phenotypic EMB 
susceptibility grew at 1 mcg/ml. All four EMR-re󰠀
sistant strains grew at concentrations of up to 2 
mcg/ml (Table 3).   
These 3 strains had different IS6110 DNA finge󰠀
rprinting profiles (Figure 1). However the IS6110  
profile of LR447 and OPR2300 were very similar 
with only one-band site difference. Their epidemi󰠀
ological correlation could not be defined.      
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Identification of strain * Concentration of EMB on LJ (mcg/ml) ** Resistance ***0 0.5 1 1.5 2 4 8
IP2342 ++++ - - - - - - Pan-S
IP2344 +++ 20 - - - - - Pan-S
IP2345 ++++ 20 - - - - - Pan-S
LR447 (406) ++ + - - - - - EMB-S
OPR1776 (306) +++ +++ + - - - - EMB-S
OPR2300 (406) +++ +++ + - - - - EMB-S
SOPR1076 (306) ++ ++ ++ ++ ++ + - EMB-R
SOPR1097 (406) +++ +++ +++ +++ +++ - _ EMB-R
OPR4440 +++ +++ +++ +++ ++ 5 - EMB-R
OPR4628 ++++ ++++ ++++ +++ ++ - - EMB-R
* Number in parenthesis beside strain indicates mutation site of embB gene 
** Number indicates actual number of colonies grown on LJ, +: 50-100 colonies; ++: 100-200 colonies; +++: 200- 
500 colonies; ++++: over 500 colonies.    
*** Pan-S: pan-susceptible; EMB-S: EMB-susceptible but resistant in other drugs; EMB-R: multi-drug resistant including 
EMB-resistant.
Table 3. EMB inhibition concentrations among strains with varying EMB resistance
Figure 1. IS6110 DNA fingerprinting profile of embB 
mutation strains. 
Lane 1: OPR1776; lane 2: LR447; lane 3: OPR2300
DISCUSSION 
The detection rate of embB mutations among 
EMB susceptible strains is variable according to 
different investigators. This variability could be 
caused by different concentrations of EMB on LJ, 
different types of media used, or sampling from 
different populations. Mokrousov et al. detected 
the embB306 mutation in 48 (31.2%) of 154 EMB- 
susceptible strains according to DST performed at 
EMB concentrations of 2 mcg/ml and 5 mcg/ml on 
LJ media8. Lee et al. detected embB mutants in 
20% (4 of 20 strains) of EMB-susceptible strains 
when using the BACTEC 460 radiometric method 
for DST7. Van Rie et al also found embB mu󰠀
tations among EMB-susceptible strains (8 of 48 
strains, 16.7%), but they found that all of them 
became EMB resistant strains in subsequent DST11.
The strains with embB mutations but phenotypic 
EMB susceptibility are commonly resistant to one 
or more anti-tuberculous drugs. To present, nobody 
has found embB mutations among pan-susceptible 
strains. We also confirmed that the absence of any 
embB mutation among 50 pan-susceptible strains, 
while 67.1% of 149 EMB-resistant strains possessed 
mutations at codons 306, 406, or 497 of the embB 
gene12. Thus, the presence of embB mutations does 
not appear to be similar to that of katG463 muta󰠀
tions, which have been described not only in INH- 
resistant but also in pan-susceptible strains13.  
We found that drug-resistant strains sometimes 
did not maintain identical DST patterns because of 
decreased viability in in vitro tests. And this phen󰠀
omenon was observed not only for resistant to 
EMB but also to RMP. Therefore we postulate 
that embB mutations at least in codons 306, 406, 
497 are correlated with EMB resistance. 
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요   약
배  경 : 
에탐부톨은 6개월 단기요법 중에 사용되는 1차 항
결핵약제 중 하나이다. embB 유전자의 돌연변이는 
에탐부톨의 내성과 관련이 있은 것으로 추측 되어 
왔다. 그러나 최근에 embB 유전자의 돌연변이는 에
탐부톨 감수성인 균에서도 발견되어 이 유전자의 돌
연변이가 에탐부톨 내성과 관련이 있는 것인지에 대
한 논란이 있는 바, 이에 대한 이해를 높이고자 본 
실험을 하게 되었다.
방  법 : 
약제감수성검사에서 에탐부톨은 감수성이지만 타 
항결핵약제에 내성을 보인 36균주를 선택하였다. 이 
균주들에서 embB 유전자에 대하여 중합효소연쇄반
응를 실시한 후에 염기서열분석을 통해 돌연변이 여
부를 조사하였다. 돌연변이가 있는 균주에 대하여 
과거의 항결핵약제 감수성검사 결과를 비교하였다.
결  과 : 
에탐부톨 감수성인 36균주 중에서 3균주(8.3%)만
이 embB 유전자의 codon 306과 codon 406에서 돌
연변이를 나타냈다. 이 균주들은 적어도 아이소니아
짓에서도 내성을 가지고 있었고, 에탐부톨 1.0 mcg/ 
ml를 함유한 LJ배지에서 모두 자랐다. 이 균주를 가
진 결핵환자들은 꾸준히 치료를 하였음에도 불구하
고 3년 동안이나 도말양성을 보였다. 또한 한 균주는 
과거의 감수성검사에서 에탐부톨에 내성을 보인 경
우도 있었다.    
결  론 : 
에탐부톨 감수성이지만 embB 유전자의 돌연변이
를 가진 균주는 균주 자체의 특성이라기 보다는 일
시적으로 생활력이 감소되어 약제 감수성으로 표현
될 수 있는 것으로 보인다.
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